Table 4.
Applied dosages and dose modifications of chemotherapy
|
Treatment and patients |
Mean dosage |
Mean number of cycles |
Patients with dose reduction |
Patients with delays |
Mean delay (range) |
Break-off current therapy line |
|---|---|---|---|---|---|---|
| % | N | N (%) | N | Days | % | |
|
1st line |
|
|
|
|
|
|
| Platinum (n = 248) |
96.1 |
3.9 |
47 (19.0)* |
101 |
15 (3–52) |
57.7 |
| For combination therapy: combined cytotoxic drug (n = 248) |
84.1 |
3.9 |
146 (58.9)* |
101 |
15 (3–52) |
57.7 |
| Monotherapy (n = 60) |
82.9 |
2.2 |
31 (51.7) |
13 |
14 (7–28) |
91.6 |
|
2nd line |
|
|
|
|
|
|
| Monotherapy (n = 117) |
95.4 |
3.2 |
20 (17.0) |
26 |
15 (4–49) |
77.7 |
| EGFR-TKI (n = 41) |
** |
4.4 |
** |
** |
** |
NA |
| Platinum-basedcombination (n = 18) |
NA |
3.6 |
14 (77.8) |
8 |
18 (4–31) |
55.6 |
|
3rd line |
|
|
|
|
|
|
| Monotherapy (n = 49) |
95.2 |
2.9 |
8 (16.3) |
9 |
12 (7–24) |
81.6 |
| EGFR-TKI (n = 36) |
** |
3.4 |
** |
** |
** |
NA |
| Platinum-basedcombination (n = 7) | NA | 3.3 | 4 (57.1) | 3 | 12 (7–21) | 71.4 |
Patients who entered clinical studies were excluded. EGFR TKI, tyrosine kinase inhibitor targeting the epidermal growth factor receptor. NA, not applicable.
*36 patients (14.5%) received a dose reduction of platinum and combined cytotoxic drug.
**no reliable data available.